肝脏渡越时间在门静脉高压-食管胃底静脉曲张患者门静脉压力评估中的应用

doi:10.13481/j.1671-587x.20190132

Abstract

Abstract: Objective: To analyze the relationship of hepatic transit time and portal vein pressure in the patients with portal hypertension and esophagogastric varices, and to clarify its clinical significance.Methods: A total of 50 hospitalized patients underwent esophagogastric venous embolization due to portal hypertension and esophagogastric varices were selected as observation group, and 50 patients without history of liver disease and clinical manifestations of liver disease (hospitalized or out-patient) were selected as control group, All patients underwent liver contrast enhanced ultrasound.The free portal pressure (FPP)was measured by ultrasound guided portal vein puncture for operating pathways in the patients in observation group. The hepatic artery-hepatic vein transit time (HA-HVTT), the hepatic portal vein-hepatic vein transit time (PV-HVTT), the liver parenchyma-hepatic vein transit time (PA-HVTT) of the patients were compared between two groups. The correlations between HA-HVTT, PV-HVTT, PA-HVTT and FPP of the patients in observation group were analyzed.Results: The HA-HVTT, PV-HVTT and PA-HVTT of the patients in observation group were significantly shorter than those in control group(t=5.078,P<0.01;t=12.163,P<0.01;t=2.649,P<0.01).The HA-HVTT, PV-HVTT and PA-HVTT had negative correlations with FPP in observation group(r=-0.799,P<0.01;r=-0.554,P<0.01;r=-0.735, P<0.01).The linear relationship between HA-HVTT and FPP was Y=-0.410X+7.254; the linear relationship between PV-HVTT and FPP was Y=-0.355X+4.983; the linear relationship between PA-HVTT and FPP was Y=-0.566X+4.997.Conclusion: Liver transit time can be used as an effective index to judge the portal vein pressure, and it can provide the theroretical basis for the diagnosis and treatment of portal hypertension in the patients.

Key words: cirrhosis, esophagogastric varices, contrast enhanced ultrasound, transit time, portal pressure

CLC Number:

R445.1

LIN Yuanqiang, JIANG Bo, LI Hequn, JIN Chunxiang, WANG Hui. Application of hepatic transit time in portal vein pressure assessment in patients with portal hypertension and esophago gastric varices[J].Journal of Jilin University(Medicine Edition), 2019, 45(01): 170-174.

References

[1] SIRLI R,SPOREA I,POPESCU A,et al. Ultrasound-based elastography for the diagnosis of portal hypertension in cirrhotics[J]. World J Gastroenterol,2015,21(41):11542-11551.
[2] THABUT D,MOREAU R,LEBREC D. Noninvasive assessment of portal hypertension in patients with cirrhosis[J]. Hepatology, 2011,53(2):683-694.
[3] ADDLEY J,THAM T C,CASH W J. Use of portal pressure studies in the management of variceal haemorrhage[J]. World J Gastrointest Endosc, 2012, 4(7):281-289.
[4] RINCON D,LOIACONO O,TEJEDOR M,et al. Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis[J]. Scand Gastroenterol,2013,48(4):487-495.
[5] QIU L,ZHANG X,LIU D, et al. Contrast-enhanced ultrasonography diagnostic evaluation of esophageal varices in patients with cirrhosis[J]. Ultrasound Q,2016,32(2):136-143.
[6] KIM M Y,SUK K T,BAIK S K,et al. Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis[J]. Hepatology, 2012,56(3):1053-1062.
[7] TAVANGAR S M,NASER RAKHSHANI N,GHODRAT MONTAZERI,et al.The effect of NAFLD(non-alcoholic fatty liver disease)on long-term outcome of chronic hepatitis B in Iranian patients[J].Open J Gastroenterol,2012,2(1):218-221.
[8] GOBEL T,ERHARDT A,HERWIG M,et al. High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe[J]. JMed Virol,2011, 83(6):968-973.
[9] BOLOGNESI M,PASCOLI M D,SACERDOTI D. Clinical role of non-invasive assessment of portal hypertension[J]. World J Gastroenterol, 2017, 23(1):1-10.
[10] KOLLER T,PIESTANSKA Z,HLAVATY T, et al. Hepatic transit times and liver elasticity compared with meld in predicting a 1 year adverse clinical outcome of a clinically diagnosed cirrhosis[J]. Vnitr Lek,2016,62(5):351-359.
[11] KUMAR A,SHARMA P,SARIN S K. Hepatic venous pressure gradient measurement:time to learn![J]. Indian J Gastroenterol,2008,27(2):74-80.
[12] RIPOLL C,GROSZMANN R,GARCIA-TSAO G,et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis[J]. Gastroenterology,2007,133(2):481-488.
[13] WANG T, LIANG F, ZHOU Z,et al. Global sensitivity analysis of hepatic venous pressure gradient (HVPG) measurement with a stochastic computational model of the hepatic circulation[J]. Comp Biol Med, 2018, 97(1):124-136.
[14] BERZIGOTTI A,PISCAGLIA E.Ultrasound in portal hypertension-part2-and EFSUMB recommendations for the performance and reporting of ultrasound examinations in portal hypertension[J].Ultraschall Med,2012,33(1):8-32.
[15] ABBATTISTA T,RIDOLFI F,CONSALVO G T,et al. Hepatic vein arrival time for diagnosis of liver cirrhosis:A 10-year single-center experience with contrast-enhanced sonography[J]. J Ultrasound Med, 2016,35(10):2121-2128.
[16] MARUYAMA H,YOKOSUKA O. Ultrasonography for noninvasive assessment of portal hypertension[J]. Gut Liver,2017, 11(4):464-473.
[17] MARUYAMA H,SHIHA G,YOKOSUKA O,et al. Non-invasive assessment of portal hypertension and liver fibrosis using contrast-enhanced ultrasonography[J]. Hepatol Int,2016,10(2):267-276.
[18] GARCIA-TSAO G,SANYAL A J, GRACE N D,et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis[J]. Hepatology,2007,46(3):922-938.
[19] GARCÍA-PAGÁN J C,GRACIA-SANCHO J,BOSCH J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis[J]. J Hepatol,2012,57(2):458-461.
[20] ZHANG C X, HU J,HU K W,et al. Noninvasive analysis of portal pressure by contrast-enhanced sonography in patients with cirrhosis[J]. J Ultrasound Med,2011,30(2):205-211.
[21] LUISA S,VITALE G,SORBO A R,et al. Hepatic vein transit time of second-generation ultrasound contrast agent:new tool in the assessment of portal hypertension[J]. J Ultrasound,2017, 20(1):43-52.
[22] ABBATTISTA T,RIDOLFI F,CIABATTONI E, et al. Diagnosis of liver cirrhosis by transit-time analysis at contrast-enhanced ultrasonography[J]. Radio Med,2008,113(6):860-874.

Application of hepatic transit time in portal vein pressure assessment in patients with portal hypertension and esophago gastric varices

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 13

Metrics

Comments

Recommended 0

[1]	NIU Meng, DENG Dayong, LI Yunpengfei, LIU Shuo, DING Jun. Values of MRE in diagnosis of stages of hepatic fibrosis:A Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 787-793.
[2]	ZHANG Lili, GU Jinhua, QI Yunfeng, ZHAO Lirong. Quantitative analysis of perfusion features of primary hepatic carcinoma in different hepatic background using contrast-enhanced ultrasound [J]. Journal of Jilin University Medicine Edition, 2016, 42(01): 164-167.
[3]	CHEN Lin, YUAN Hong, ZHU Longdong, YUE Wei, LI Min, CHENG Zeyi, LI Wenxuan. Influence of second infection in risk of death of hospitalized patients with cirrhosis [J]. Journal of Jilin University Medicine Edition, 2015, 41(04): 820-824.
[4]	LIU Chen， XU Chang-yan，LI Guo-dong，CHI Bao-rong. Analysis of clinical features of patients with autoimmune hepatitis/primary biliary cirrhosis overlap syndrome [J]. Journal of Jilin University Medicine Edition, 2014, 40(03): 646-649.
[5]	CONG Xiang-guo,SUN Zhong-hua,GAO Ying,HU Hong-lei. Detection of serum thyroid hormone levels in patients with nephrotic syndrome and decompensated cirrhosis and their clinical significances [J]. J4, 2012, 38(6): 1201-1208.
[6]	NIE Rong-hui\|LIU Yuan-yuan. Application of detection of tumor markers AFP,CA125,CA199 and CEA in diagnosis and treatment for patients with hepatitis and liver cirrhosis [J]. J4, 2012, 38(1): 119-122.
[7]	ZHAO Yue,WANG Run-lan,MEI Li,YANG Xiao-ying. Assessment of regional left ventricular systolic function of patients with late-stage liver cirrhosis by VSI [J]. J4, 2011, 37(1): 150-153.
[8]	CHEN Yong-sheng,LI Dong-fu,LIU Xiao-yang,ZHOU Jian. Effect of HBV replication on levels of IL-12 and IL-18 in peripheral blood in patients with hepatitis B-related cirrhosis [J]. J4, 2008, 34(6): 1038-1041.
[9]	ZHANG Xue-chun，CHENG Xin-sheng，DU Xiao-hong，WANG Wei-guo. Protective effect of glycine on intestinal barrier of rats with obstructive jaundice [J]. J4, 2007, 33(3): 499-502.
[10]	CHEN Li-gang, Chi Bao-rong. Significance of pathological changes and prognosis in chronic hepatic disease by assay of plasma level of neuropeptide Y [J]. J4, 2006, 32(1): 113-3.
[11]	WANG Ying-kai, CHI Bao-rong, SUN Bo, WANH Zhi-hao. Establishment and stability of hepatic cirrhosis rat models [J]. J4, 2005, 31(6): 893-895.
[12]	WANG Yan-ling,CHEN Yun-bo,DING Wei,LI Gui-ying,WANG Shu-min,LI Ai-jing. AEffects of Cimetidine on portal hemodynamics in dogs with cirrhosis and portal hypertension [J]. J4, 2005, 31(2): 268-271.
[13]	JIN Zhen-jing, CHI Bao-rong, MA Li-na, ZHAO Wen-jing ,YUAN Kun. Expression of connective tissue growth factor-mRNAin experimental hepatic fibrosis [J]. J4, 2005, 31(1): 55-57.